Other Clinical Trial - Oxygen Saturation & Perfusion Index ın Neonates at

Status Completed

Clinical Trial Summary

Congenital heart diseases are among the most common congenital anomalies and occur with an incidence of approximately 8ınd12 / 1,000 live births worldwide. This figure does not cover minor lesions such as bicuspid aortic valves and small atrial or ventricular septal defects. Most of these defects do not need treatment or treatment is needed after infancy. Other defects are severe and usually require early treatment in the neonatal period. Critical congenital heart disease is defined as structural heart defects that are associated with hypoxia in the neonatal period and have significant morbidity and mortality potential in early life. Critical congenital heart disease is estimated to be ~3 in 1000 live births. It is estimated that 50% of congenital heart diseases are detected by prenatal ultrasound. Even if a standard neonatal examination is performed, 13 to 55% of patients with critical congenital heart disease can be discharged from the hospital without being diagnosed.

Screening of infants with non-invasive oxygen saturation measurement has been proposed as an adjunct to early detection of critical congenital heart disease.

The American Academy of Pediatrics, the American Cardiology Foundation and the American Heart Association have targeted 7 specific lesions for the pulse oximetry screening protocol: truncus arteriosus, transposition of the great arteries, tricuspid atresia, tetralogy of Fallot, total pulmonary venous return anomaly, hypoplastic left heart syndrome and pulmonary atresia.

The reference values of peripheral perfusion (PPI) index has been established for normal newborns between 1 and 120 h of age.

Lower PPI values than 0.70 may indicate illness. Including cut-off values for PPI in pulse-oximetry screening for duct dependent congenital heart disease is a promising tool for improving the detection of critical congenital heart disease with duct-dependent systemic circulation.

We aimed to investigate screening critical congenital heart disease and also to establish normal values of oxygen saturation and perfusion index at high altitude.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Altitude Sickness
Critical Congenital Heart Disease
Heart Diseases
High Altitude

Clinical Trial Details

NCT number	NCT04290481
Study type	Observational
Source	Ataturk University
Contact
Status	Completed
Phase
Start date	June 1, 2018
Completion date	February 1, 2019

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT06133530` - Human Milk Oligosaccharides (HMOs) and Gut Microbiota, Immune System in Antarctica	N/A
Completed	`NCT02233582` - Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDS) on Acclimatization to High Altitude	Phase 1
Active, not recruiting	`NCT04604249` - Prevalence of COVID-19 in High Altitude : Insights From the Highest City of the World
Not yet recruiting	`NCT05063643` - Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude
Recruiting	`NCT05474287` - SJOV vs. HFNO for Hypoxia During Procedural Sedation at High Altitudes	N/A
Completed	`NCT06392373` - High Altitude Muscle Recovery	N/A
Completed	`NCT03851744` - High Altitude and Exogenous Carbohydrate Oxidation	N/A
Completed	`NCT01830530` - HIGH Altitude CArdiovascular REsearch in the ANDES	Phase 4
Completed	`NCT06164665` - Effects of Pioglitazone on Exogenous Carbohydrate Oxidation During Steady-State Exercise at High Altitude	Phase 4
Recruiting	`NCT06393998` - CO2 Supplement for Treatment of Acute Mountain Sickness	N/A
Not yet recruiting	`NCT06446427` - The Effect of Acute High Altitude Exposure on Rescuer Performance and Patient Care	N/A
Completed	`NCT04915378` - Hypoxia-altitude Testing to Predict Altitude Related Adverse Health Effects in Chronic Obstructive Pulmonary Disease (COPD) Patients
Completed	`NCT05798416` - Effect of Inhalation of Low Dose CO2 on Exercise Performance at High Altitude	N/A
Completed	`NCT05715476` - The Effect of Different Altitude Levels on Spinal Anesthesia in Cesarean Section Surgery	N/A
Recruiting	`NCT05115721` - Establishing the Reference Interval for Pulse Oxygen Saturation in Neonates at High Altitude
Recruiting	`NCT06152744` - Evaluation of Membrane Lung Function in High-altitude Regions
Recruiting	`NCT05304923` - Supraglottic Jet Oxygenation and Ventilation for Gastrointestinal Endoscopy at High-altitude	N/A
Recruiting	`NCT04199650` - Definition of ARDS in Qinghai Province: Verification of Berlin Definition Plateau Criteria

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Oxygen Saturation and Perfusion Index ın Neonates at High Altitude

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms